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Efficacy of Ranolazine in
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Observations From the Randomized,
Double-Blind, Placebo-Controlled MERLIN–TIMI
(Metabolic Efficiency With Ranolazine for Less Ischemia in
Non–ST-Segment Elevation Acute Coronary Syndromes) 36 Trial
Sean R. Wilson, MD,* Benjamin M. Scirica, MD, MPH,*† Eugene Braunwald, MD,*†
Sabina A. Murphy, MPH,* Ewa Karwatowska-Prokopczuk, MD, PHD,‡ Jacqueline L. Buros, BA,*
Bernard R. Chaitman, MD,§ David A. Morrow, MD, MPH*†
Boston, Massachusetts; Palo Alto, California; and St. Louis, Missouri
Objectives We aimed to evaluate the efficacy and safety of ranolazine in a larger and more diverse group of patients with
angina than previously studied.
Background Ranolazine is an antianginal shown to reduce angina and improve exercise performance in selected patients
with early-positive exercise testing and those with frequent angina.
Methods We investigated the antianginal effects of ranolazine in the subgroup of patients with prior chronic angina (n 
3,565, 54%) enrolled in the randomized, double-blind, placebo-controlled MERLIN–TIMI (Metabolic Efficiency
With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes) 36 trial of patients with
acute coronary syndrome. Follow-up was a median of 350 days.
Results Patients with prior angina received evidence-based therapy (95% aspirin, 78% statins, 89% beta-blockers, aver-
age 2.9 antianginal agents). The primary end point (cardiovascular death, myocardial infarction, recurrent ischemia)
was less frequent with ranolazine (hazard ratio [HR]: 0.86; 95% confidence interval [CI]: 0.75 to 0.97; p 
0.017), due entirely to a significant reduction in recurrent ischemia (HR: 0.78; 95% CI: 0.67 to 0.91; p  0.002).
Ranolazine also reduced worsening angina (HR: 0.77; 95% CI: 0.59 to 1.00; p  0.048) and intensification of
antianginal therapy (HR: 0.77; 95% CI: 0.64 to 0.92, p  0.005). Exercise duration at 8 months was greater with
ranolazine (514 s vs. 482 s, p  0.002). Cardiovascular death or myocardial infarction did not differ between
treatment groups (HR: 0.97; 95% CI: 0.80 to 1.16; p  0.71). Symptomatic documented arrhythmias (2.9% vs.
2.9%, p  0.92) and total mortality (6.2% vs. 6.4%, p  0.96) were similar with ranolazine or placebo.
Conclusions In this largest study of ranolazine in patients with established coronary artery disease, ranolazine was effective
in reducing angina with favorable safety in a substantially broader group of patients with angina than previously
studied. (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes;
NCT00099788) (J Am Coll Cardiol 2009;53:1510–6) © 2009 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.01.037a
(
b
t
D
h
C
S
fhronic angina impairs functional capacity and quality of life
nd is associated with decreased economic productivity (1–4).
espite the aggressive use of medical therapies and myocardial
evascularization procedures, angina remains highly prevalent,
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April 28, 2009:1510–6 Ranolazine in Patients With Chronic Anginancidence and prevalence of patients with angina is anticipated
o increase in the coming decade as a result of the aging
f the population, the worsening epidemic of obesity, and
he greater use of life-prolonging therapies (5,7).
Ranolazine, the first member of a new class of medica-
ions approved in the U.S. in 2006 for the treatment of
ngina, is a piperazine derivative that seems to exert its
nti-ischemic effects through antagonism of the late phase
f the inward sodium current that is increased in myocardial
schemia and contributes to detrimental cellular sodium and
alcium overload (8–12). Ranolazine was studied as mono-
herapy in 175 patients with exercise-limiting angina and
ignificant ST-segment depression between 3 and 9 min on
n exercise tolerance test (ETT) using the modified Bruce
rotocol (13). Ranolazine was also tested in combination
ith other antianginal agents in 791 patients meeting the
ame ETT criteria (14) and in 565 patients with at least 3
pisodes of angina/week on the maximum dose of amlodip-
ne (15). Together, this experience in approximately 1,500
elected patients with chronic angina showed that ranola-
ine improved exercise performance and reduced angina
requency and the use of sublingual nitroglycerin. Ranola-
ine had not yet been studied in a more diverse population
f patients with chronic angina.
Therefore, we performed a pre-specified analysis of the
ntianginal efficacy and safety of ranolazine in the subgroup
f 3,565 patients with a history of chronic angina who
resented with an acute coronary syndrome (ACS) and were
nrolled in the MERLIN–TIMI (Metabolic Efficiency with
anolazine for Less Ischemia in Non-ST-Segment Eleva-
ion Acute Coronary Syndromes) 36 trial (16).
ethods
atient population. The MERLIN–TIMI 36 trial was a
ultinational, randomized, double-blind, placebo-
ontrolled parallel group trial of ranolazine in patients with
non–ST-segment elevation ACS. The design and primary
esults of the trial have been published previously (16,17).
tudy patients had a clinical presentation consistent with an
CS with at least 1 indicator of moderate to high risk of
eath or recurrent ischemic events. All patients were as-
essed for a history of prior stable angina before and separate
rom the presenting ACS, and the information was col-
ected on the case report form. In addition, the severity of
ngina at 1 month before randomization was classified with
he Canadian Cardiovascular Society classification (CCSC)
ystem. Timing of the most recent revascularization proce-
ure and history of known stenosis 50% were also re-
orded. Exclusion criteria included clinically significant
epatic disease, end-stage renal disease requiring dialysis,
reatment with agents known to prolong the QT interval,
ardiogenic shock, persistent ST-segment elevation, or a
ife-expectancy 12 months. ltudy protocol. Patients were
andomized in a 1:1 ratio to re-
eive intravenous ranolazine fol-
owed by oral ranolazine or
atching placebo. After 12 to 96 h
f the intravenous formulation,
tudy medication (ranolazine
xtended-release or placebo) was
o be continued orally at a dose of
,000 mg twice daily until the end
f the study. Individuals with renal
nsufficiency (estimated creatinine
learance 30 ml/min) received
00 mg twice daily. In addition,
rotocol-defined dose reductions
ere made for subjects with per-
istent and profound prolongation
f the QT interval or specific ad-
erse events potentially related to study drug, including nausea,
izziness, or orthostatic hypotension. Individuals received stan-
ard medical and interventional therapy as dictated by local
ractice guidelines.
nd points. The primary efficacy end point of the trial was
he first occurrence of any element of the composite of
ardiovascular death, myocardial infarction (MI), or recur-
ent ischemia. The definition of MI has been reported in
etail (17). Recurrent ischemia was pre-specified as any of
he following: 1) recurrent ischemia with electrocardio-
raphic changes; 2) recurrent ischemia leading to hospital
tay; 3) recurrent ischemia prompting revascularization; and
) worsening angina/ischemia requiring additional therapy
s defined by an increase in angina to a higher CCSC
equiring new or increasing doses of antianginal medications
n response to the symptom change. End points specifically
esigned to assess the efficacy of ranolazine as antianginal
herapy included worsening angina as defined in the pre-
eding text, the need for an increase or addition of any
ntianginal therapy, and exercise duration on treadmill or
icycle ETT performed at 8 months (or final visit, which-
ver was sooner). All elements of the primary efficacy end
oint as well as symptomatic documented arrhythmia were
djudicated by a blinded clinical events committee. The
TT results were interpreted by a core laboratory (St.
ouis, Missouri) blinded to treatment allocation and out-
omes. As part of an efficacy and safety analysis, all patients
ad a continuous electrocardiographic recording (Lifecard
F, DelMar Reynolds/Spacelabs, Issaquah, Washington)
erformed during the first 7 days after randomization.
olter recordings were interpretable in 97% of subjects with
median duration of 6.8 days (17). Recordings were
valuated in the Thrombolysis In Myocardial Infarction
ore Laboratory by reviewers blinded to treatment assign-
ent and clinical outcome. The incidence of clinically
ignificant arrhythmias detected on Holter monitoring was
re-specified as an episode of ventricular tachycardia of at
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
CAD  coronary artery
disease
CCSC  Canadian
Cardiovascular Society
classification
CI  confidence interval
ETT  exercise tolerance
test
HR  hazard ratio
MI  myocardial infarction
PCI  percutaneous
coronary interventioneast 100 beats/min for 3 or more beats, supraventricular
t
b
m
S
a
a
d
c
c
p
t
H
e
E
m
t
A
a
f
t
R
O
a
i
O
w
a
m
a
C
a
s
a
p
a
r
p
O
k
i
h
B
D
†
i
1512 Wilson et al. JACC Vol. 53, No. 17, 2009
Ranolazine in Patients With Chronic Angina April 28, 2009:1510–6achycardia of at least 120 beats/min for 4 or more beats,
radycardia of 45 beats/min for 4 or more beats, pauses of
ore than 2.5 s, or third-degree heart block (17).
tatistical analysis. These analyses were planned explor-
tory analyses of efficacy and safety included in the statistical
nalysis plan that was finalized before locking the trial
atabase. Baseline characteristics were compared with the
hi-square test for categorical variables and the t test for
ontinuous variables. All comparisons of elements of the
rimary efficacy end point were performed with the log-rank
est conducted according to the intention-to-treat principle.
azard ratios (HRs) and 95% confidence intervals (CIs) were
stimated with a Cox proportional-hazards regression model.
vent rates are presented as Kaplan-Meier failure rates at 12
onths. A landmark analysis was also conducted to evaluate
he effect of ranolazine starting from 30 days to end of study.
nalyses of safety were conducted in the safety cohort defined
s those who received at least 1 dose of study drug.
The authors had full access to and take full responsibility
or the integrity of the data. All authors have read and agree
o the paper as written.
aseline Characteristics of Patients With Prior Chronic Angina by R
Table 1 Baseline Characteristics of Patients With Prior Chronic
Characteristics R
Age, yrs, median (25th, 75th)
Age 75 yrs
Female sex
White race
Weight, kg, median (25th, 75th)
Risk factors for atherosclerosis
Diabetes mellitus
Hypertension
Hyperlipidemia
Current smoker
Cardiac history
Prior MI
Prior heart failure
Prior coronary revascularization (PCI or CABG)
Prior known stenosis 50%
CCSC at 1 month before enrollment
0–I
II
III–IV
Estimated creatinine clearance 60 ml/min*
Coronary angiography during the index hospital stay
Cardiac medications during index hospital stay and/or discharge
Aspirin
Thienopyridine
Beta-blocker
Calcium-channel blocker†
Long acting nitrate†
ACE inhibitor or angiotensin II receptor blocker
Statin
ata are expressed as n/total (%) unless otherwise specified. Systeme International unit conversio
at discharge.
ACE  angiotensin-converting enzyme; CABG  coronary artery bypass graft; CCSC  Canadian Ca
ntervention.esults
f the 6,560 patients enrolled in the trial, 3,565 (54%) had
history of prior chronic angina. The presenting character-
stics of those with and without prior angina are provided in
nline Table 1A. The presenting characteristics of those
ith prior angina, who comprised the cohort for this
nalysis, were well-balanced between the randomized treat-
ent groups (Table 1). The mean duration of chronic
ngina was 5.2 years. The majority of patients were in
CSC class 2 (41%), with 32% reporting more severe
nginal symptoms (CCSC score 3) at 1 month before
tudy entry (Table 1). Evidence-based therapies for second-
ry prevention were used in a high proportion of the
opulation, including aspirin in 95%, beta-blockers in 89%,
nd statins in 78%, and were similarly balanced between the
anolazine and placebo groups. More than one-third of
atients had a history of prior revascularization (Table 1).
f those in whom the timing of prior revascularization was
nown (n  866), 448 underwent percutaneous coronary
ntervention (PCI) in the prior 24 months, of which 315
ad PCI performed in the past 12 months before study
mized Treatment Group
ina by Randomized Treatment Group
ine (n  1,789) Placebo (n  1,776) p Value
5 (57, 73) 66 (56, 73) 0.98
/1,789 (18.7) 346/1,776 (19.5) 0.54
/1,789 (35.8) 693/1,776 (39.0) 0.045
/1,789 (94.4) 1,697/1,776 (95.6) 0.12
0 (72, 91) 80 (71, 91) 0.40
/1,789 (36.9) 689/1,776 (38.8) 0.24
/1,781 (82.5) 1,461/1,764 (82.8) 0.79
/1,630 (74.2) 1,199/1,601 (74.9) 0.64
/1,788 (21.5) 367/1,776 (20.7) 0.55
/1,769 (45.3) 756/1,756 (43.1) 0.18
/1,789 (25.7) 464/1,776 (26.1) 0.78
/1,789 (34.9) 566/1,775 (31.9) 0.058
72/768 (87.5) 667/744 (89.7) 0.19
/1,766 (27.8) 431/1,750 (24.6) 0.011
/1,766 (42.1) 715/1,750 (40.9)
/1,766 (30.1) 604/1,750 (34.5)
/1,784 (23.8) 436/1,769 (24.6) 0.57
/1,789 (49.9) 853/1,776 (48.0) 0.26
/1,789 (95.4) 1,691/1,776 (95.2) 0.77
/1,789 (55.2) 984/1,776 (55.4) 0.91
/1,789 (88.0) 1,598/1,776 (90.0) 0.064
/1,789 (30.4) 570/1,776 (32.1) 0.28
/1,789 (40.7) 747/1,776 (42.1) 0.41
/1,789 (79.7) 1,462/1,776 (82.3) 0.047
/1,789 (78.4) 1,362/1,776 (76.7) 0.21
nvert creatinine clearance to ml/s, multiply by 0.0167. *Estimated with Cockroft-Gault equation;ando
Ang
anolaz
6
334
640
1,689
8
660
1,469
1,209
384
801
460
624
6
491
743
532
425
893
1,707
988
1,575
544
728
1,426
1,403
n: to cordiovascular Society classification; MI  myocardial infarction; PCI  percutaneous coronary
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April 28, 2009:1510–6 Ranolazine in Patients With Chronic Anginantry. Coronary angiography was also undertaken in 49% of
atients during the index hospital stay. The median dura-
ion of follow-up was 350 days (25th, 75th percentiles: 237,
60). Only 5 patients (0.14%) with prior angina were lost to
ollow-up. The mean number of antianginal agents admin-
stered at hospital discharge to patients with prior angina
as 1.9 with no difference between treatment groups (p 
.20). A calcium-channel blocker or nitrate was adminis-
ered in 58% of patients. Over the entire duration of
ollow-up, the mean number of antianginals used/patient
as 2.9, with 67.5% of patients treated with 2 or more
edication classes.
fficacy of ranolazine as antianginal therapy. Among
atients with prior angina, the primary end point (cardio-
ascular death, MI, or recurrent ischemia) was lower in
atients treated with ranolazine compared with placebo
25.2% vs. 29.4%, HR: 0.86; 95% CI: 0.75 to 0.97; p 
.017); however, this effect was driven entirely by the impact
f ranolazine on recurrent ischemia. Ranolazine had no
ffect on the risk of cardiovascular death or MI in the
atients with prior angina (HR: 0.97; 95% CI: 0.80 to 1.16,
 0.71), consistent with the result in the overall cohort
16). In contrast, ranolazine significantly reduced the inci-
ence of each of the major end points with respect to its
ntianginal efficacy (Fig. 1). Specifically, compared with
lacebo, ranolazine reduced the incidence of recurrent
schemia (HR: 0.78; 95% CI: 0.67 to 0.91; p  0.002),
orsening angina (HR: 0.77; 95% CI: 0.59 to 1.00; p 
.048), and intensification of antianginal therapy (HR: 0.77;
5% CI: 0.64 to 0.92, p  0.005). Moreover, in those with
rior angina, ranolazine also improved severe recurrent
schemia, defined as ischemia associated with new electro-
ardiographic changes or leading to hospital stay or revas-
ularization (11.9% vs. 14.4%; HR: 0.81; 95% CI: 0.67 to
.98; p  0.026) (Table 2). Notably, in patients without
rior angina, there was no detectable benefit of ranolazine
Figure 1 Antianginal Effects of Ranolazine
Effect of ranolazine compared with placebo on angina and recurrent ischemia
in patients with a history of chronic angina who have presented with an acute
coronary syndrome. CI  confidence interval; HR  hazard ratio.ith respect to recurrent ischemia (HR: 1.03; 95% CI: 0.81
o 1.29, p  0.83).
This effect of ranolazine on the primary end point and
ecurrent ischemia was consistent in patients with prior
ngina who were treated with an early invasive management
trategy (n  1,184; HR: 0.75; 95% CI: 0.60 to 0.94; p 
.013; and HR: 0.71; 95% CI: 0.54 to 0.94; p  0.015,
espectively). Also, when the analysis was restricted to
atients with a history of moderate or more severe angina
CCSC 2 to 4) 1 month before enrollment (n  2,594), the
ffect of ranolazine remained apparent with respect to the
rimary composite end point (HR: 0.83; 95% CI: 0.72 to
.97; p  0.016) and recurrent ischemia (HR: 0.75; 95%
I: 0.63 to 0.91; p  0.0026).
The number of classes of traditional antianginal drugs
sed/subject was shifted slightly toward fewer with ranola-
ine (p  0.004) such that 65% of patients assigned to
anolazine received 2 or more classes compared with 70% of
hose allocated to placebo. The mean number of traditional
ntianginal agents across all visits was decreased, albeit
odestly, in patients treated with ranolazine (2.8 vs. 2.9,
 0.045).
In a landmark analysis conducted to evaluate the chronic
ffect of ranolazine after the first 30 days, ranolazine reduced
he incidence of recurrent ischemia (HR: 0.80; 95% CI:
.67 to 0.96; p  0.015), worsening angina (HR: 0.76; 95%
I: 0.58 to 0.99; p  0.044), and intensification of other
ntianginal therapy (HR: 0.77; 95% CI: 0.64 to 0.93; p 
.007) (Table 2). In addition, when evaluated at 8 months
or the final visit if sooner), ranolazine significantly im-
roved all metrics of exercise performance on ETT or
icycle exercise testing (Table 3). Exercise duration (least
quares mean  SEM) was 514  7 s with ranolazine,
ompared with 482  7 s with placebo (p  0.002). A
reatment effect was also observed for the time to onset of
ngina: 508  7 s in the ranolazine group versus 477  7 s
n the placebo group (p  0.002). In addition, the time to
nset of 1-mm ST-segment depression was 509 7 s versus
79  7 s (p  0.003). Among patients undergoing
readmill testing (n  1,459), which was the primary study
ssessment in prior studies of ranolazine, the mean differ-
nce in exercise duration compared with placebo was 44 s
589  10 s vs. 545  10 s, p  0.001). There was no
ignificant impact of ranolazine on exercise duration (p 
.14) or time to ischemia on exercise testing (p  0.17) in
hose without a history of stable angina, consistent with the
ack of effect on recurrent ischemia in patients without prior
ngina.
afety and tolerability. Ranolazine was generally well-
olerated in patients with prior angina. The most common
dverse effects that were more frequent in the ranolazine
roup compared with placebo were dizziness (12.4% vs.
.4%), nausea (9.7% vs. 6.1%), and constipation (8.5% vs.
.3%). Ranolazine was discontinued due to an adverse event
n 8.1% of subjects compared with 4.1% receiving placebo (p0.001). During oral treatment, the dose of ranolazine was
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Ranolazine in Patients With Chronic Angina April 28, 2009:1510–6ecreased in 190 (10.6%) patients—18 patients (1.0%) for
enal dysfunction, 10 patients (0.6%) for persistent prolon-
ation of the corrected QT interval, 154 patients (8.6%) for
dverse events, and 8 patients for unknown reasons.
There was no difference in the incidence of the major
afety end points in patients with prior angina treated with
anolazine versus placebo (Table 4). Specifically, death from
ny cause did not differ between treatment groups (HR:
.01; 95% CI: 0.78 to 1.30; p 0.96). Sudden cardiac death
lso did not differ with ranolazine compared with placebo
HR: 0.81; 95% CI: 0.53 to 1.25, p  0.35). Similarly, no
ignificant increase in frequency of symptomatic docu-
ented arrhythmias was observed with ranolazine (risk
atio: 0.98; 95% CI: 0.67 to 1.43; p  0.92). Clinically
ignificant arrhythmias on Holter evaluation were signifi-
antly lower in the ranolazine group (73.9% vs. 83.1%, p 
.0001), including ventricular tachycardia 8 beats (5.2%
s. 8.7%, p  0.0001).
Because of the inhibitory effect of diltiazem and vera-
amil on the clearance of ranolazine, we examined the
olerability in those patients receiving these agents. Of those
atients with prior angina, at the time of hospital discharge,
07 were treated with diltiazem (n 219) and/or verapamil
n  96) in combination with study drug. The incidence of
iscontinuation of ranolazine for an adverse event was
igher with ranolazine compared with placebo (11.7% vs.
.1%, p  0.048), similarly to those treated without these
alcium-channel blockers.
fficacy Outcomes
Table 2 Efficacy Outcomes
Ranolazine (n  1,789)
Randomization to end of study
Primary end point* 443 (25.2)
Major secondary end point† 379 (21.2)
CV death or MI 214 (11.9)
Recurrent ischemia 277 (16.5)
Worsening angina 96 (5.6)
Severe recurrent ischemia 204 (11.9)
Intensification of antianginal therapy 205 (12.5)
30 days until end of study (Landmark analysis)
Primary end point 338 (19.8)
Recurrent ischemia 226 (13.7)
Worsening angina 92 (5.4)
ata are reported as n (%). Event rates in parentheses are Kaplan-Meier estimates (%) at 1 year.
ecurrent ischemia.
CI  confidence interval.
erformance on ETT at 8 Months (s, mean  SEM)
Table 3 Performance on ETT at 8 Months (s, mean  SEM)
Ranolazine
(n  1,190)
Placebo
(n  1,173) p Value
Total duration 514 7 482 7 0.002
Time to 1-mm ST-segment
depression
509 7 479 7 0.003
Time to onset of angina 508 7 477 7 0.002tTT exercise tolerance test.iscussion
his analysis of more than 3,500 patients with established
oronary artery disease (CAD) and chronic angina treated
ith ranolazine or placebo for approximately 1 year more
han doubles the total experience with ranolazine from prior
hase 3 trials and extends its evaluation as antianginal
herapy to a substantially more heterogeneous population
han previously studied. We found that ranolazine was
ffective as an antianginal, reducing the incidence of recur-
ent ischemia by 22% with a corresponding 24% reduction
n the incidence of worsening angina and improvement in
xercise performance on treadmill testing. In addition, there
as no excess of all-cause mortality, sudden cardiac death,
r symptomatic documented arrhythmia in this high-risk
roup with ischemic heart disease treated with ranolazine,
ompared with placebo. Our findings also confirmed that,
espite its efficacy as an antianginal, ranolazine did not
mpact the incidence of cardiovascular death or MI over the
uration studied in this trial, nor did ranolazine offer a
etectable improvement in outcomes or symptoms in pa-
ients with CAD without chronic angina. The results of this
nalysis therefore offer additional insight that is useful in
efining the clinical role for this newer agent for treatment
f patients with ischemic heart disease. On the basis of this
vidence, ranolazine is an effective antianginal and anti-
schemic agent but is not useful as a disease-modifying
econdary preventive therapy or for prophylaxis of recurrent
ngina in asymptomatic patients stabilized after an ACS.
anagement of angina and clinical implications. Angina
s a prevalent and morbid condition with respect to its
dverse impact on quality of life. Among patients with a
istory of angina, the frequency of exacerbations is the most
mportant determinant of quality of life (18). For these
easons, guidelines from the American Heart Association
nd American College of Cardiology emphasize dual goals
or the management of patients with chronic CAD: first,
Placebo (n  1,776) Hazard Ratio (95% CI) p Value
503 (29.4) 0.86 (0.75–0.97) 0.017
414 (23.5) 0.89 (0.78–1.03) 0.12
221 (12.5) 0.97 (0.80–1.16) 0.71
344 (21.1) 0.78 (0.67–0.91) 0.002
124 (8.1) 0.77 (0.59–1.00) 0.048
245 (14.4) 0.81 (0.67–0.98) 0.026
260 (16.4) 0.77 (0.64–0.92) 0.005
386 (23.3) 0.86 (0.74–0.99) 0.039
274 (17.2) 0.80 (0.67–0.96) 0.015
120 (7.9) 0.76 (0.58–0.99) 0.044
ovascular (CV) death, myocardial infarction (MI), or recurrent ischemia. †CV death, MI, or severe*Cardihe secondary prevention of cardiovascular death and MI,
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April 28, 2009:1510–6 Ranolazine in Patients With Chronic Anginand second, the amelioration of angina (5). These guidelines
lso recommend an approach that includes consideration of
oth pharmacological and invasive therapies in order to
chieve optimal results with respect to these dual objectives.
he results of the COURAGE (Clinical Outcomes Utiliz-
ng Revascularization and Aggressive Drug Evaluation) trial
19)—which showed no difference between aggressive sec-
ndary preventive pharmacotherapy plus PCI compared
ith optimal medical therapy alone with respect to the
ncidence of death or MI—confirmed that a strategy of
nitial optimal medical therapy is reasonable for most
atients with stable CAD and that medical therapy and PCI
re important complementary options for managing angina.
Notably, even with aggressive pharmacotherapy and re-
ascularization, approximately 25% of patients with chronic
ngina continue to experience attacks with contemporary
herapy (20,21). Moreover, even after treatment for a
ecognized MI, nearly 1 in 5 patients will have recurrence of
ngina by 1 year (22). In addition, use of traditional
ntianginal agents is limited in some patients by side effects
5). Therefore, it is not surprising that population-based
tudies demonstrate that 65% of patients with chronic stable
ngina require more than 1 antianginal agent to control
heir symptoms (23). For these reasons, there has been a
ustained interest in newer antianginal agents that might
dd effectively to traditional options for treatment of angina,
articularly those that act without affecting heart rate or
lood pressure.
Our findings provide strong evidence that ranolazine can
dd to contemporary therapy for relief of symptoms in
atients with chronic angina. The group of patients with
rior chronic angina enrolled in the MERLIN–TIMI 36
rial share many of the clinical features of patients enrolled
n the COURAGE trial (19); compared with patients
ithout prior angina, they had a higher prevalence of risk
actors for atherosclerosis, more extensive cardiac history
nd clinical comorbidities, and a greater need for antianginal
edications at discharge. These findings identify an impor-
ant subset of patients with chronic angina who seem to
erive clinical benefit (reduced angina and ischemia) with
anolazine. Importantly, the reduction in worsening angina
nd improvement in exercise capacity that we observed
ccurred in patients with high-risk ischemic heart disease
ut without stringent selection criteria based upon early
ailure during exercise testing or extremely frequent angina.
afety and Tolerability Outcomes
Table 4 Safety and Tolerability Outcomes
Major Safety End Points* Ranolazine (n  1
Death from any cause 111 (6.2)
Sudden cardiac death 37 (2.0)
Symptomatic documented arrhythmias 52 (2.9)
Clinically significant arrhythmias on Holter evaluation† 1,279/1,730 (73
Safety population. †Denominators are for those with evaluable Holter data available.
CI  confidence interval.n addition, the beneficial effect of ranolazine with respect eo recurrent ischemia occurred on the background of tradi-
ional antianginal therapy and evidence-based therapies for
econdary prevention. These findings therefore complement
he results of prior trials of ranolazine in patients with
hronic angina and expand the studied population to one
ore reflective of the broad population with ischemic heart
isease. Notably, ranolazine has not been shown to improve
ardiovascular survival, as is the case for calcium-channel
lockers and nitrates (5,24). Therefore, given the associated
urvival benefit in patients with prior MI, there remains a
ationale for prioritization of beta-blockers in patients
ithout contraindications. Our findings indicate that rano-
azine is among the effective therapeutic options for treat-
ent of angina. Moreover, previous studies have established
ts unique properties as an antianginal that exerts its
nti-ischemic effects without an impact on heart rate and
lood pressure (8). Therefore, ranolazine might be particu-
arly useful when treatment is limited by bradycardia or
ypotension.
tudy limitations. Given the neutral primary efficacy anal-
sis of the MERLIN–TIMI 36 trial of ranolazine for
eduction of major cardiovascular events (16), all additional
nalyses, including this one, must be regarded as inherently
xploratory. However, on the basis of pre-existing data from
maller trials in patients with chronic angina, there was
strong a priori basis for evaluation of this pre-defined
ubgroup. Second, the overall population of patients studied
n the MERLIN–TIMI 36 trial was selected on the basis of
heir presentation with an ACS, and thus they represent a
igh-risk subset of patients with established ischemic heart
isease. Nevertheless, given that the pathophysiology and
atural history of chronic angina in patients with a history of
CS is typical of that for patients with stable CAD, our
ndings are likely to be relevant to patients with established
schemic heart disease in the absence of recent ACS.
oreover, this assertion is supported by the consistent
ndings with ranolazine in the preceding smaller trials
mong selected patients with stable CAD (13–15). Lastly,
ecause randomization was not stratified by a history of
rior angina, small differences in clinical characteristics
etween those randomized to ranolazine or placebo exist
Table 1). A supportive analysis adjusting for those covari-
tes with significant or borderline imbalances (sex, prior
evascularization, CCSC, and beta-blocker and angiotensin-
onverting enzyme inhibitor use) showed no qualitative differ-
Placebo (n  1,775) Hazard Ratio (95% CI) p Value
114 (6.4) 1.01 (0.78–1.30) 0.96
46 (2.4) 0.81 (0.53–1.25) 0.35
52 (2.9) 0.98 (0.67–1.43) 0.92
1,448/1,743 (83.1) NA 0.001,785)
.9)nce in the results (ranolazine vs. placebo for primary end point
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schemia HR: 0.78; 95% CI: 0.67 to 0.93, p  0.004). It
hould also be noted that by design the landmark analysis
erformed starting at 30 days is limited to the selected subset
f survivors to that time point and should be regarded as
xploratory.
onclusions
n this largest study of ranolazine in patients with estab-
ished CAD, ranolazine was effective in reducing angina and
ecurrent ischemia in a substantially broader group of
atients with angina than previously studied with a favor-
ble overall profile of safety in a high-risk group of patients.
anolazine is an option to be considered in the optimal
edical therapy of patients with chronic angina.
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APPENDIX
or a supplementary table on the baseline characteristics of patients with
nd without prior chronic angina, please see the online version of this
rticle.
